AbbVie (NYSE:ABBV) Trading Down 2.9% – What’s Next?
by Sarita Garza · The Markets DailyShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) fell 2.9% during mid-day trading on Thursday . The stock traded as low as $207.71 and last traded at $208.7890. 5,083,567 shares traded hands during trading, a decline of 31% from the average session volume of 7,317,118 shares. The stock had previously closed at $214.98.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on ABBV. Guggenheim reissued a “buy” rating on shares of AbbVie in a research report on Thursday, March 12th. UBS Group cut their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Citigroup decreased their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. The Goldman Sachs Group restated a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.
Check Out Our Latest Research Report on AbbVie
AbbVie Stock Performance
The stock has a market capitalization of $369.17 billion, a PE ratio of 88.47, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. The business’s 50-day moving average is $221.58 and its two-hundred day moving average is $224.41.
AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.
AbbVie Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.
Insider Buying and Selling
In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is currently owned by insiders.
Institutional Investors Weigh In On AbbVie
Several institutional investors have recently made changes to their positions in the stock. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie in the second quarter valued at about $26,000. Chelsea Counsel Co. acquired a new position in AbbVie during the third quarter worth about $26,000. Litman Gregory Wealth Management LLC purchased a new position in AbbVie in the fourth quarter valued at about $28,000. Westend Capital Management LLC purchased a new position in AbbVie in the fourth quarter valued at about $29,000. Finally, Imprint Wealth LLC lifted its position in shares of AbbVie by 56.3% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.